Intensifying trade tensions, political instability, and increased regulatory scrutiny took their toll on global M&A activity in 2018. The number of deals struck over the year fell slightly for the first time since 2010 to 19,232 after steadily rising f…
A “magnet for talent” – really? Would you want to join an organization that is in the midst of such turmoil?
President Trump promised “voluntary massive drops in prices” from Big Pharma. Americans are skeptical.
Our slow progress against pancreatic cancer is representative of the war on cancer writ large. Focus in on pancreatic cancer, and you see that there has been progress for patients with some subtypes for the disease. There are real reasons for hope that…
Biotechnology stocks were some of the strongest performing stocks from 2009-2015. Then, the biotech bubble burst and just about every major biotech stock plunged into a private bear market.
Big pharma companies need to buy innovation, biotech companies are getting sky-high valuations, and 2018 is shaping up to be the second biggest M&A year for the sector on record.
